Cure My Disease

Don't miss your cure!

 Log in / Sign up

PRP and a daily pill: a new combo for ED?

NCT ID NCT07602608

Disease control Sponsor: Benha University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 156 men with mild to mild-moderate erectile dysfunction who had not responded well to previous treatments. Half received platelet-rich plasma (PRP) injections into the penis plus a daily 5 mg tadalafil pill, while the other half got PRP injections alone. The goal was to see if adding tadalafil leads to better erectile function over six months, measured by questionnaires and ultrasound blood flow tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Platelet-rich plasma (PRP) and tadalafil
What this could lead to
If it works, this could point toward a more effective combination treatment for erectile dysfunction using PRP and a daily pill.
What could go wrong
This is a completed Phase 4 trial with 156 men, but results may not apply to all ED patients. Adding tadalafil may not provide extra benefit over PRP alone, and PRP injections carry risks like pain or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

160 people

The number who actually took part.

Started

Apr 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult men aged 18 years or older. * Diagnosis of mild to mild-moderate erectile dysfunction according to the International Index of Erectile Function-5. * Inadequate response to previous phosphodiesterase type 5 inhibitor treatment. * Eligible for intracavernosal platelet-rich plasma injection. * Eligible for oral tadalafil treatment. * Baseline penile duplex Doppler ultrasound assessment available. Exclusion Criteria: * Severe erectile dysfunction. * Peyronie's disease. * Previous major pelvic surgery. * Previous pelvic trauma. * Known bleeding or coagulation disorder. * Contraindication to phosphodiesterase type 5 inhibitors, including nitrate therapy. * Significant cardiac disease contraindicating tadalafil use. * Total testosterone less than 300 nanograms per deciliter. * Refusal or inability to provide written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Erectile dysfunction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

erectile dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Erectile dysfunction

Contacts and locations

Locations

  • Benha University Hospital

    Banhā, Qalyubia Governorate, 13511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.